Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). (2018)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1038/s41416-018-0123-9

PubMed Identifier: 30131546

Publication URI: http://europepmc.org/abstract/MED/30131546

Type: Journal Article/Review

Volume: 119

Parent Publication: British journal of cancer

Issue: 9

ISSN: 0007-0920